CSF3 and acute myeloid leukemia: Furthermore, comparing the percentages of normal STs of the AML+CYT+GCSF-treated groups 4 weeks and 5.5 weeks post-injection shows an increase of 17%–42%, which may suggest that the positive effect of GCSF on the histology of the STs needs more time to manifest when added to the CYT regimen of treatment.